Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)

Exclusion Criteria

• •1. Experienced systemic infection during past three months;
• •2. Neck surgery was performed within 3 months;
• •3. Previous endovascular interventional treatment involving the aortic arch was performed;
• •4. Infectious aortic disease、Takayasu arteritis，Marfan syndrome (or other connective tissue diseases );
• •5. Severe stenosis, calcification, thrombosis, or tortuosity of the carotid or subclavian artery;
• •6. Heart transplant;
• •7. Suffered MI or stroke during past three months;
• •8. Class IV heart function (NYHA classification);
• •9. Active peptic ulcers or upper gastrointestinal bleeding occurring within the previous three months;
• •10. Hematological abnormality, defined as follows: Leukopenia (WBC \< 3 × 109/L), acute anemia (Hb \< 90 g/L); thrombocytopenia (PLT count \< 50 × 109/L), history of bleeding or coagulopathy;
• •11. Renal insufficiency， creatinine \> 265 umol/L (or 3.0mg/dL) and/or end-stage renal disease requiring renal dialysis, as determined by an investigator after a thorough analysis;
• •12. Pregnant or breastfeeding;
• •13. Allergies to contrast agents;
• •14. Life expectancy of less than 12 months;
• •15. Participating in another drug or device research;
• •16. Any other disease or abnormality that the investigators believe may hinder endovascular interventional treatment.